Clinical Impact of Sarcopenia Screening on Long‐Term Mortality in Patients Undergoing Coronary Bypass Grafting

Seung Hun Lee,Jinhwan Jo,Jeong Hoon Yang,Sung Mok Kim,Ki Hong Choi,Young Bin Song,Dong Seop Jeong,Joo Myung Lee,Taek Kyu Park,Joo‐Yong Hahn,Seung‐Hyuk Choi,Su Ryeun Chung,Yang Hyun Cho,Kiick Sung,Wook Sung Kim,Hyeon‐Cheol Gwon,Young Tak Lee
DOI: https://doi.org/10.1002/jcsm.13645
2024-11-10
Journal of Cachexia Sarcopenia and Muscle
Abstract:Background Sarcopenia is an aging‐related condition characterized by loss of skeletal muscle mass and is an indicator of subclinical atherosclerosis. The relationship between reduced muscle mass and long‐term clinical outcomes in patients with advanced coronary artery disease who have undergone coronary artery bypass grafting (CABG) is not fully understood. This study is sought to evaluate the prognostic implications of sarcopenia screening in patients undergoing CABG. Methods A total of 2810 patients who underwent CABG were analysed and classified according to presence of reduced muscle mass. The skeletal muscle index (SMI) was calculated as L3 muscle area (cm2)/height (m)2 on computed tomography. Reduced SMI was defined as SMI ≤ 45 cm2/m2 in male and ≤ 38 cm2/m2 in female. The primary outcome was all‐cause mortality, and survival analysis was performed using the Kaplan–Meier method and compared with the log‐rank test. Results The median follow‐up was 8.7 years, and 924 patients (32.9%) had reduced SMI. Patients with reduced SMI were older (67.7 ± 8.8 vs. 62.2 ± 9.8 years; p
medicine, general & internal,geriatrics & gerontology,gerontology
What problem does this paper attempt to address?